Intech Investment Management LLC Takes $753,000 Position in Omnicell, Inc. (NASDAQ:OMCL)

Intech Investment Management LLC acquired a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 17,270 shares of the company’s stock, valued at approximately $753,000.

A number of other large investors also recently bought and sold shares of OMCL. Vanguard Group Inc. lifted its stake in shares of Omnicell by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock worth $165,200,000 after purchasing an additional 80,312 shares during the last quarter. Pacer Advisors Inc. lifted its position in shares of Omnicell by 32.6% during the second quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock valued at $56,047,000 after buying an additional 508,789 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Omnicell by 0.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock valued at $31,955,000 after buying an additional 3,570 shares in the last quarter. Victory Capital Management Inc. grew its position in shares of Omnicell by 11,982.3% in the 3rd quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after buying an additional 1,138,921 shares during the last quarter. Finally, Federated Hermes Inc. raised its stake in shares of Omnicell by 1,113.6% during the 2nd quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock worth $26,830,000 after acquiring an additional 909,480 shares in the last quarter. Institutional investors own 97.70% of the company’s stock.

Omnicell Price Performance

NASDAQ OMCL opened at $46.59 on Friday. The stock’s fifty day moving average price is $44.55 and its 200 day moving average price is $37.94. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $55.74. The company has a market cap of $2.16 billion, a price-to-earnings ratio of -119.46, a PEG ratio of 36.82 and a beta of 0.81.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Craig Hallum raised their target price on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Bank of America reissued a “neutral” rating and issued a $57.00 price objective (up previously from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. Wells Fargo & Company upped their target price on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research report on Monday, October 14th. JPMorgan Chase & Co. increased their price target on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Finally, Benchmark restated a “buy” rating and set a $48.00 price target on shares of Omnicell in a research note on Wednesday, October 9th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $52.00.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.